April 27, 2015
Germany’s Bayer HealthCare said on April 24 that it has filed its radioactive therapeutic agent radium-223 dichloride in Japan for the treatment of prostate cancer patients with bone metastases. Radium-223 is a therapeutic alpha particle-emitting pharmaceutical with an anti-tumor effect...read more